The association of high body mass index with the safety and efficacy of sacituzumab govitecan in patients with metastatic triple-negative breast cancer from the ASCENT study

By sjmartinez • June 4, 2025

García-Estévez L, Bardia A, Rugo HS, Carey LA, Diéras VC, Loibl S, Piccart M, Gianni L, Kalinsky K, O'Shaughnessy J, Hurvitz SA, Harting E, Valdez T, Phan S, Lai C, Cortés J. The association of high body mass index with the safety and efficacy of sacituzumab govitecan in patients with metastatic triple-negative breast cancer from the ASCENT study. ESMO Open. 2025 Jun 2;10(6):105294. doi: 10.1016/j.esmoop.2025.105294. Epub ahead of print. PMID: 40460679.

Tags: Antibody–drug conjugate, body mass index, Hematology/Oncology, metastatic triple-negative breast cancer, Obesity, Publications, Sacituzumab govitecan

Early cellular events of osteomucosal healing in the tooth extraction socket

Kim S, Song M, Williams D, Du W, Cho I, Bae E, Kim J, Goswami A, Shin KH, Park NH, Kim RH. Early cellular events[...]

A treatment-impact model of alectinib for the prediction of recurrence and associated costs in treating resectable ALK+ non-small cell lung cancer

Cummings AL, Sussell J, Rosettie KL, Moustaid FE, Ogale S, Ngiam C, Jovanoski N, Arnold M, Lee JM. A treatment-impact model of alectinib for the[...]

A novel application of LC-MS/MS accurately quantifies the labile redox pools of cellular coenzymes Q9 and Q10

Jain A, Li VW, Salem J, Reddy ST, Palaskas NJ, Meriwether D. A novel application of LC-MS/MS accurately quantifies the labile redox pools of cellular[...]